Actinium Pharmaceuticals Inc. is a clinical stage biotech focused on improving patient access and outcomes to cellular therapies such as BMT and CAR-T with its proprietary targeted conditioning technology. Actinium is the only company with a late stage, multi-disease, multi-target pipeline focused on targeted conditioning. Its technology is enabled by Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes.